inject sale smooth humira loe
concern reinstat neutral po
allergan mostli stabil post humira loe
reinstat coverag neutral rate po investor
long penal over-reli humira sale given
impend loe perceiv inabl mitig top-line eros
understand discount peer due uncertainti top-lin resili think
allergan allevi sale drop-off partial stabil busi
question much view magnitud humira eros still like
give investor paus impact pipelin allergan deal still
digest assess crux neutral thesi still assum discount
multipl peer heroic vs reflect expect
declin sale peer isnt like materi better
overal argu share fairli reflect headwind humira eros
off-set allergan new product portfolio wait greater clariti
impact pipelin newer product put money work stock
sever product drive overal sentiment
suspect humira sale unlik fall cliff especi ou sale
indic guid would character us loe
assumpt conserv move humira sale
howev brand loyalti lack biosimilar
experi us may mitig downsid skyrizi psoriasi rinvoq rheumatoid
arthriti see strong launch crowd indic make
forecast conserv bofa con guidanc slow launch
orilissa endometriosi pain add downsid risk guidanc
bofa con inflect point believ non-humira sale
could reach risk-adjust basi includ allergan forecast
fall short albeit conserv pipelin assumpt
full definit iqmethod sm measur see page
bofa secur seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price
object basis/risk page
net dbt
loe loss exclus
ou outsid unit state
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
research-bas global pharmaceut
busi spun abbott
develop market drug area
immunolog virolog oncolog
move away relianc humira
requir growth newli launch drug
allergan maintain top-lin level
opportun creat upsid non-humira sale
still seen signific competit
 market newli launch
blockbust rinvoq skyrizi need captur
go long-develop transit lose patent protect
humira sell pharmaceut drug world-wide ww sale diversifi
revenu base compani still time us patent humira expir
pace deal revenu diversif step although
think aggress drop-off may help growth compar suspect
market eros take five year humira lose
sale estim us humira sale declin y/i first year
provid reason cadenc allow newli launch drug rinvoq skyrizi
off-set top-lin eros hematolog asset imbruvica
provid stabl sale near term loe provid concern
critic time transit overal think allergan transact
adequ job stabil top-lin howev combin entiti doesnt provid
signific growth opportun busi develop like need
bolt-on transact see room share run come month
integr proce expect ceil price appreci dividend yield
decreas revenu concentr persist neutral share given
expect tight trade window dust settl investor digest
pro-forma outlook new see exhibit base bull bear case
number event could chang thesi swing share
buy categori first sign brand loyalti limit biosimilar uptak would
limit declin us humira sale would provid
direct upsid valuat po assumpt also guid non-
humira risk-adjust sale forecast consensu
short numbershould pipelin deliv number late stage asset
would certainli see room share run justifi re-rat addit
leav allergan medic aesthet busi botox juvaderm coolsculpt
stand-alone core unit function high capac remain
seen valu add busi see possibl scenario
unlock valu sale use proce purchas higher growth
pharmaceut compani allergan transact expect produc
cost synergi addit acceler opportun improv oper expens
time could help bottom line improv cash flow
competit uniqu among biopharma compani face threat
number differ front current five fda approv humira biosimilar
expect pipelin given humira revenu pie aggress
price amongst biosimilar entrant like lead larg discount sway payer
move away humira skyrizi rinvoq launch heavili competit
market earli metric thu far posit could run headwind
tri captur addit market share entrench competitor addit
abbvi orilissaapprov endometriosi current await approv
uterin fibroidsi expect gener peak sale per
estim far less bullish opportun peak sale in-lin
consensu recogn five quarter sale per quarter
estim may optimist uterin fibroid approv need add signific
valu reach estim combin aggress biosimilar entri
materi deceler skyrizi rinvoq prescript lack orilissa
acceler would certainli chang sentiment turn us bearish
note base case assum price-to-earnings multipl bull case assum price-to-earnings multipl bear case assum price-to-earnings multipl cagr unless otherwis note
creat follow separ unlock
valu humira lead anti-tumor necrosi factor anti-tnf drug
humira franchis blockbust number one sell drug world-wide
sale mix histori diversifi revenu base
year one year stand-alone compani attempt buy shire
reduc tax burden redomicil oversea walk away
deal pay shire treasuri impos new rule chang
quest addit revenu success acquir pharmacycl larg
imbruvica steadi contributor top-line growth
follow year went search diversif acquir privately-
held stemcentrx oncolog asset rova-t antibody-drug conjug
see drug subsequ fail scrap pipelin
announc intent acquir allergan investor question
impact deal potenti maxim diversif
reli heavili humira relianc increas time due
increas number approv indic across inflamm immunolog
upon spin-out abbott humira account total sale four year
later humira account revenu ou patent expir
humira contribut approxim total sale inde
near time us loss exclus loe patent cliff humira
expect event persist overhang stock given
success humira number approv biosimilar product alreadi approv
wait take market share understand signific impact
loe lost ou patent protect humira drug declin
first full year biosimilar competit follow declin
expect ou
despit concentr humira achiev diversif
hematology/oncolog divisioncompos imbruvica venclextawhich
contribut approxim sale imbruvica kinas inhibitor
use hematology/oncolog adult numer condit includ chronic
margin zone lymphoma chronic graft versu host diseas
collabor agreement provid janssen part johnson johnson cover
bob hopkin exclus commerci imbruvica ou co-exclus
janssen us janssen share pre-tax profit loss equal
commerci product sale imbruvica includ net revenu
janssen share includ cog venclexta inhibitor
current approv treatment chronic lymphocyt leukemia acut myeloid
leukemia profit share roche/genentech cover sachin jain
graham parri split oper profit within us ou
book sale pay royalti net sale
addit hematology/oncolog portfolio also hcv hepat
viru franchisecompos mavyret viekirathat contribut
sale enanta entitl mileston royalti compon hcv
regimen doubl digit royalti mavyret sale viekira sale
addit three key divis hem/onc hcv compani also sizabl
revenu gener product includ creon pancreat enzym replac
treatment orilissa gonadotropin-releas hormon receptor antagonist among
other contribut sale collect orilissa
exclus global right neurocrin cover tazeen ahmad receiv mileston
payment royalti book sale revenu royalti part cog
howev import part stori sever product lupron synthroid
synagi expect flat growth
state union
coheru
seen exhibit histor lag major pharma peer drg index
respect forward price-to-earnings multipl sinc revenu base grown
dramat ep cagr street long
seen concentr risk patent cliff humira play import role
peer-trail multipl brief respit trail multipl investor
ralli behind share move forward price-to-earnings multipl line drg
averag time mavyret approv
patent victori protect humira franchis long howev polit
commentari quickli sent group continu slide report
failur rova-t forward price-to-earnings subsequ steadi declin low
august allergan deal announc rebound sinc
current multipl immedi announc allergan
transact investor uncertainti drove stock low
share subsequ approach sell recent impact
stand-alone share certainli lag vs peer
dont see near-term thesi deserv addit turn surpass other
better growth prospect
rate declin humira patent loss import metric
share assum us sale declin
base case far initi us declin seen expect
blockbustersneulasta rituxan avastin herceptin
far consensu see exhibit current expect
decreas respect outsid us
humira lost exclus led signific ou declin
expect declin
given number compani wait launch biosimilar dont see
scenario us humira sale fall margin first year
loss patent protect convers also dont see case sale declin
aggress given expect biolog blockbust therefor
expect cadenc declin humira reason cadenc
allow pipelin name rinvoq skyrizi continu grow market share
off-set humira eros
current approv biosimilar abrilada approv hadlima
samsung bioepi hyrimoz novarti cyltezo boehring ingelheim
amjevita expect could come futur
biosimilar histor slow captur market share biosimilar remicad
signific price reduct provid meaning option payer reduc cost
view rapid price reduct like given number biosimilar
launch need gain favor payer formulari access
exhibit blockbust drug declin loe million
look blockbust face patent expir note
remicad neulasta rituxan avastin herceptin multibillion dollar product
see gener competit biosimilar seen exhibit first
year drop-off rang vari show signific declin
therefor believ high end assumpt first year
appropri given number biosimilar wait enter market addit
remicad biosimilar enter skeptic biosimilar market eas
us biosimilar enter therefor expect favor payer uptak
reiter conserv assumpt
exhibit pro-forma revenu contribut billion
note assum allergan transact close may
model signific declin concern dramat drop humira patent
expiri impact share overst view seen
exhibit combin allergan product see peak sale
repres growth compound-annual-growth-rate given
initi yearli declin still expect minim compound-annual-growth-rate
top-line sale certainli growth stock mean
manag reduc impact humira patent cliff offset growth
franchis stabil revenu provid attract cash flow busi
exhibit consensu humira estim time
seen exhibit humira consensu sale expect bloomberg
trend year estim increas
sinc earli humira franchis look durabl lead us loe
howev current estim in-lin origin expect
estim lower almost origin model headlin risk
like remain believ humira concern alreadi price share see less
risk downsid base humira sale alon fact believ slower declin
biosimilar entri could help meaning improv consensu estim keep revenu
number elev provid tailwind share seen exhibit
provid sensit analysi impact dcf percent declin us
sale first second year patent expiri
exhibit abbvi sensit analysi base us humira dcf
allergan inject sale littl growth
announc intent purchas allergan impli
ev/ebitda multipl almost discount pharmaceut
peer believ acquisit allergan make littl strateg sens
innov perspectivelack signific futur growth enginebut
reason job off-set inevit declin humira share recogn
requir larger transact allergan help slow bleed provid
base signific cash flow sizabl dividend current dividend yield seen
exhibit believ acquir allergan strateg point share
trade around stock fallen juli high
allergan unpopular stock street assign averag target
price time buy hold sell inher valu
limit growth driver investor get excit well recent launch
compet drug jeuveau allergan lead botox franchis
report busi
unit sale
report pfizer
botox provid top-lin stabil grow market
botox franchis account allergan sale total
therapeut cosmet despit approv year ago lack
patent protect brand loyalti botox enabl allergan build maintain
recognit grow aesthet market predominantli cash pay provid
addit upsid therapeut migrain dont see estim aggress
next decad equat compound-annual-growth-rate
attain blend market size price increas
monitor close say think allergan nice
job term botox competit look strategi look
growth strong realli impact competit
look variou liabil noth chang view express time
close time announc
certainli see bear thesi botox come launch competitor jeuveau
prabotulinumtoxina approv earli sale
year jeuveau alreadi surpass xeomin becom third lead toxin
cosmet procedur botox franchis seen competitor nestl
dysport sale y/i merz xeomin privat recent launch
jeuveau pois take market share physician check
prefer botox amongst establish physician familiar comfort
brand howev less establish plastic surgeon seem prefer jeuveau
given attract price practic focus non-surg
procedur prefer better margin one physician spoke believ jeuveau
may pose greater challeng botox given dose eas use
smart thing jeuveau equival dose botox dont
think use one know botox sinc ive use
long dysport xeomin think dose sound small
make thing complex need without ad benefit
recent announc creat subsidiari aesthet busi
consist botox juvederm coolsculpt stand alon rest
allergan product absorb busi expect juvederm sale
increas expect coolsculpt busi
go certainli ad signific growth
come year move make aesthet busi stand-alone potenti
signal option divis spun later manag believ leav
divis limit disrupt allow bucket core
busi area immunolog hematology/oncolog medic aesthet
central nervou system dont anticip sell medic aesthet
divis near term unit could provid option cash infus
could use acquir higher growth opportun futur
hematolog steadi competit loom
start guid sale imbruvica venclexta combin
revenu combin sale believ number
achiev note competit next-gener btk inhibitor could mute growth
later year imbruvica goe patent first mover
advantag clinician therefor familiar use imbruvica overal view
imbruvica maintain lead posit limit patient switch
head-to-head btk data emerg venclexta combin therapi certainli add
valu combin cost imbruvica could pose challeng use
first-lin could also mitig uptak later line overal would character
consensu number bit high side consid manag guid
combin sale street estim current howev
high start
exhibit stand-alone sale expect million
imbruvica growth engin two main hematolog product
sale expect revenu loe near term
number data readout imbruvica help increas penetr rate
time help increment grow franchis main question imbruvica
whether withstand competit next-gener bruton tyrosin kinas
btk inhibitor specif calquenc brukinsa
calquenc astrazeneca cover eu analyst graham parri sachin jain
drug approv octob mantl cell lymphoma novemb
chronic lymphocyt leukemia larger market opportun abbvi
note call calquenc sale significantli
impact imbruvica franchis launch cll expect head head
trial primari endpoint month elevate-rr may readout may
provid headwind calquenc show improv efficaci favor side effect
calquenc market think two year realli
abl get label real differenti today approv indic
mcl second-lin plu share share quit
time kind vacil area quit time current use cll
call
head-to-head differ compar arm exhibit show result
imbruvica trial imbruvica vs chlorambucil patient year
previous untreat cll calquenc elevate-tn obinutuzumab
combin chlorambucil calquenc combin obinutuzumab
calquenc monotherapi subject previous untreat cll see result
studi competit pave way increas competit cll
btk inhibitor work follow-on btk inhibitor efficaci
exhibit imbruvica vs calquenc head-to-head
result discontinu
month
month
major compet product brukinsa beigen cover yang huang
approv novemb relapsed/refractori mantl cell lymphoma
still earli mcl launch brukinsa recent fail show superior phase
head-to-head trial vs imbruvica waldenstrom macroglobulinemia chart
vgpr cr rate brukinsa vs imbruvica fail
distinguish brukinsa superior therapi brukinsa on-going phase trial
alpin compar brukinsa vs imbruvica patient relapsed/refractori cll
enrol expect complet sometim data expect
given similar albeit statist signific result expect brukinsa
potenti take market share imbruvica futur lead lower
consensu estim
grade higher ae
ae lead treatment discon
ae lead dose reduct
venclexta current approv cll aml contribut
sale given imbruvica strength expect venclexta slower ramp
clinician get certain risk tumor lysi syndrom
comfort use drug especi among commun physician howev
venclexta potenti drug holiday provid compel opportun addit
efficaci see sale ramp
overli concern note venclexta receiv condit approv late
base phase studi acut myeloid leukemia aml combin
azacitidin decitabin low-dos cytarabin ldac recent one phase
confirmatori trial ldac viale-c fail significantli extend patient live
ldac alon result decreas risk death ldac alon
extens live month vs month ldac statist signific
despit show clinic activ howev subsequ demonstr
combin venclexta-azacitidin viale-a met dual primari endpoint overal
surviv os composit complet remiss rate cr recogn aml market
opportun much less cll market mix result certainli dont add
venclexta stori current ascrib peak sale venclexta aml
skyrizi/rinvoq rise star competit space
abbvi star pipelin drug recent approv product skyrizi rinvoq
signific driver growth help mitig humira eros
high aspir product note potenti captur humira
type sale unadjust basi certainli see
assumpt blue-ski given launch competit
inflamm immunolog landscap see number addit
entrant well mainstay treatment go patent guid earli
expect skyrizi rinvoq sale combin sale
believ reason anticip competit headwind like
produc combin sale closer vs consensu drug certainli
place market current question expect await
detail launch addit indic assess peak potenti
skyrizi monoclon antibodi direct subunit
drug approv treatment moder sever plaqu psoriasi adult
candid system therapi phototherapi drug
alreadi run rate produc sale two phase studi
plaqu psoriasi patient skyrizi went head-to-head stelara show
patient achiev respons rate trial versu stelara
patient placebo patient futur indic crohn diseas ulcer
coliti psoriat arthriti atop dermat hidraden suppurativa provid
addit upsid franchis come year seen exhibit skyrizi
sale expect fluctuat low earli peak
recent trend bit current
exhibit consensu skyrizi rinvoq sale time billion
seen exhibit number line extens skyrizi pursu
major part thesi manag believ irrit bowel
diseas ibd crohn ulcer coliti market could signific one given
space current underserv therapeut standpoint howev note
area like see intens competit anti-tnf humira remicad cimzia
biolog stelara tremfya mirikizumab entyvio well asset
studi assess efficaci safeti risankizumab subject moder sever
activ crohn diseas fail prior biolog treatment primari endpoint patient
endoscop respons week patient clinic remiss per daili stool
frequenc averag daili abdomin pain score week
studi efficaci safeti risankizumab subject moder sever activ
crohn diseas primari endpoint patient endoscop respons week
patient clinic remiss per daili stool frequenc averag daili abdomin pain
score week
studi compar risankizumab placebo subject activ psoriat arthriti includ
histori inadequ respons intoler biolog therapi primari
endpoint particip achiev least improv week
studi compar risankizumab placebo subject activ psoriat arthriti
histori inadequ respons intoler least one diseas modifi anti-
rheumat drug dmard therapi primari endpoint particip achiev
improv week
studi evalu efficaci safeti risankizumab subject moder sever
activ ulcer coliti fail prior biolog therapi primari endpoint
particip clinic remiss per adapt mayo score week
studi evalu risankizumab adult adolesc subject moder sever atop
dermat primari endpoint particip achiev reduct baselin
eczema area sever index easi
seen exhibit skyrizi rinvoq strong launch trx
count mirror individu success sinc launch expect continu
growth continu launch add indic come year
note skyrizi inject trend late like due
impact wherea rinvoq tablet see less impact due
rinvoq upadacitinib newest approv drug immunolog space
specif heavili competit rheumatoid arthriti space drug select
inhibitor display approxim fold select
respectivelythrough rinvoq abil bind two separ site
approv come patient moder sever activ rheumatoid arthriti
inadequ respons intoler methotrex howev success
rinvoq clear home run gilead galapago filgotinib also select
inhibitor compet patient class jak also black box warn
fdawhich start pfizer xeljanz increas risk blood clot
death could rais concern physician may tamper expect
class drug black box warn relat concern drug increas rate
thrombosi embol current model peak rinvoq sale
studi efficaci safeti upadacitinib subject moder sever activ
crohn diseas inadequ respond intoler biolog therapi primari
endpoint proport particip clinic remiss week proport
particip endoscop respons week
studi efficaci safeti upadacitinib subject moder sever activ
crohn diseas inadequ respond intoler convent and/or biolog
therapi primari endpoint proport particip clinic remiss week
proport particip endoscop respons week
studi evalu efficaci safeti upadacitinib subject moder sever
activ ulcer coliti primari endpoint subject achiev clinic remiss per adapt
studi assess efficaci safeti upadacitinib combin topic corticosteroid
treatment adolesc adult particip moder sever atop dermat
candid system therapi primari endpoint particip achiev
reduct easi week subject achiev viga-ad least two
grade reduct week
studi assess efficaci safeti upadacitinib treatment adolesc adult
particip moder sever atop dermat candid system therapi
primari endpoint particip achiev reduct easi week
subject achiev viga-ad least two grade reduct week
studi compar safeti efficaci upadacitinib dupilumab adult subject
moder sever atop dermat primari endpoint subject reduct easi
studi evalu safeti efficaci upadacitinib subject giant cell arter primari
endpoint patient achiev sustain remiss
studi evalu efficaci safeti upadacitinib adult subject axial spondyloarhr
primari endpoint particip achiev assess asa
final abbvi orilissa uptak slow despit potenti blockbust
potenti sale sale per quarter still
believ orilissa signific long term opportun compani exceed
sale manag note new endometriosi drug
decad educ need creat awar new therapi
howev given lacklust launch model sale in-lin
consensu second leg growth orilissa uterin fibroid non-surg
treatment fairli limit women afflict competit myovant obseva
work oral gnrh could impact long term prospect bayer iliaprisan
also wait wing believ still time orilissa
blockbust expect signific headwind remain conserv sale potenti
pipelin potenti remain seen
number asset pipelin combin compani line
extens current approv product major futur develop
certainli potenti upsid approv product believ
expect current factor dont see novel multipl blockbust
come pipelin near term drive signific upsid outlin
major one
exhibit market drug expand label opportun
america global research compani report
r/r cll
allergan recent approv migrain drug ubrelvi ubrogep pipelin asset
atogep pair nice allergan entrench sale forc botox ubrelvi
calcitonin gene-rel peptid cgrp antagonist recent approv acut
treatment migrain without aura adult migrain certainli larg
market major mild-to-moder moderate-to-sever patient receiv non-
steroid anti-inflammatori drug nsaid triptan ubrelvi target acut
migrain patient popul contraind triptan current model sale
ubrelvi vs consensu atogep also cgrp
develop prevent chronic episod migrain phase data
episod migrain prevent studi expect sometim
current model peak sale atogep vs consensu
antagonist biolog develop treatment
ulcer coliti phase data expect sometim current
model peak sale slightli ahead consensu
abicipar design ankyrin repeat protein darpin direct bind vegf-a
isoform similar lucenti higher affin longer intraocular half-lif
fda recent accept bla patient wet age-rel macular degener
pdufa decis expect sometim current model peak sale
slightli ahead consensu
part approv process allergan enter agreement divest brazikumab
inhibitor similar mechan skyriziw see posit
skyrizi like superior product two astrazeneca agre
acquir brazikumab inclus global develop commerci right
asset divest zenpep pancrelipas exocrin pancreat
insuffici due cystic fibrosi condit acquir nestl
exhibit select consensu pipelin sale expect million
believ advanc program late stage pipelin includ
navitoclax expect sale vs con
treatment advanc parkinson diseas peak sale vs con
peak sale veliparib parp inhibitor includ peak sale
valuat approach share employ blend averag
discount cash flow analysi price-to-earnings multipl base larg cap global
therapeut group price object reflect blend averag
discount cash flow analysi price-to-earnings multipl analysi deriv compar larg
cap pharma compani indic intrins valu discount rate
termin valu price-to-earnings multipl respect
analyz share use discount cash flow analysi assum weight
averag cost capit wacc termin growth rate see exhibit
assumpt dcf suggest intrins valu approxim
per share repres upsid current share level dcf valuat
impli price-to-earnings multipl repres discount current peer ntm
averag assum price-to-earnings addit stress test dcf
assumpt wacc termin growth rate get better sens potenti
fluctuat valuat see exhibit
seen exhibit incom statement assum full integr
transact allergan assumpt assum allergan transact close
may assum pro-forma revenu expect peak
right humira patent expiri declin
acquir process non-gaap
acquisit debt certainli weigh abbvi balanc sheet expect
robust cash flow pay debt quickli believ debt
paid target net debt/ebitda debt
expect paid may alon expect chang
share outstand transact assum signific extra cash flow
design debt pay expect cash flow avail
continu grow dividend least sustain singl digit
increas thereaft seen exhibit current highest
debt/ebitda amongst peer assum compani debt/ebitda
reduc near end sustain dividend
exhibit debt level biopharmaceut peer million
cash equival
prepaid expens
liabil equiti
current portion long-term debt
account payabl accru liabil
accumul comprehens incom
total liabil equiti
price object po base blend valuat dcf
non-gaap ep estim price-to-earnings multipl give valu assum
wacc estim arriv dcf valuat
downsid risk earlier-than-anticip launch humira biosimilar us
 integr risk clinic pipelin failur reduc cash flow gener
pay debt dividend
geoff meacham herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
compani
qualiti earn
iqmethod smi set bofa global research standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa global research
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
